Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Zentalis Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ZNTL
Nasdaq
2836
zentalis.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jun 2nd, 2025 3:00 pm
Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024)
- May 16th, 2025 4:08 am
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
- May 14th, 2025 2:05 pm
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- May 1st, 2025 3:00 pm
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
- Apr 29th, 2025 9:00 am
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
- Apr 28th, 2025 6:00 am
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
- Apr 23rd, 2025 2:05 pm
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
- Mar 26th, 2025 2:05 pm
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
- Mar 25th, 2025 2:40 pm
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
- Mar 15th, 2025 9:25 am
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
- Mar 3rd, 2025 6:00 am
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Feb 24th, 2025 2:05 pm
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently
- Feb 20th, 2025 10:21 pm
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Feb 3rd, 2025 7:35 am
Zentalis price target lowered to $10 from $20 at Oppenheimer
- Jan 30th, 2025 8:20 am
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
- Jan 29th, 2025 5:00 am
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
- Jan 28th, 2025 2:05 pm
US Exchange Penny Stocks To Watch In January 2025
- Jan 28th, 2025 6:06 am
Zentalis Pharma Says FDA Grants Fast Track Status on Azenosertib Cancer Drug Candidate
- Jan 9th, 2025 10:40 am
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Jan 9th, 2025 10:00 am
Scroll